Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss clinical progress in Small Cell Lung Cancer (SCLC)

OBR Peer-Spectives

Small Cell Lung Cancer (SCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss clinical progress in small cell lung cancer (SCLC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center speaks with Melissa Johnson, MD, Program Director, Lung Cancer Research, Sarah Cannon Research Institute, discuss the different driver mutations in Non Small Cell Lung Cancer (NSCLC) and how to use them to guide treatment

Non Small Cell Lung Cancer (NSCLC) – Robert Figlin, MD, and Melissa Johnson, MD, discuss the different driver mutations in non small cell lung cancer (NSCLC)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Arjun Balar, MD, Director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discuss clinical progress in bladder cancer

Bladder Cancer – Robert Figlin, MD, and Arjun Balar, MD, discuss clinical progress in bladder cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Adam Brufsky, MD, PhD, Professor of Medicine, Associate Division Chief for the Division of Hematology/Oncology, UPMC, discuss clinical highlights from SABCS 2020

Breast Cancer – Robert Figlin, MD, and Adam Brufsky, MD, PhD, discuss clinical highlights from SABCS 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Mazyar Shadman, MD, MPH, Associate Professor, Clinical Research Division Fred Hutchinson Cancer Research Center, discuss clinical highlights in the treatment of CLL from ASH 2020

Chronic Lymphocytic Leukemia (CLL) – Robert Figlin, MD, and Mazyar Shadman, MD, MPH, discuss clinical highlights from ASH 2020

In this episode of CANCER BUZZ from the Association of Community Cancer Centers (ACCC), we discuss how healthcare providers and policymakers can work together to pave the future of telehealth beyond the current public health emergency. Now that the barriers to telehealth have tumbled on an unprecedented scale, it’s doubtful future healthcare delivery will maintain […]

Telehealth After COVID-19

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Acute myeloid leukemia (AML) and Acute lymphocytic leukemia (ALL) – David Sallman, MD, and Robert Figlin, MD, discuss clinical highlights from ASH 2020

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer

Gastric/GE Junction Cancer – Geoffrey Ku, MD, and Robert Figlin, MD, discuss recent clinical developments in gastric and esophageal cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)

Non Small Cell Lung Cancer – Victoria Villaflor, MD, and Robert Figlin, MD, discuss unresectable stage III NSCLC

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate-9ER and other I-O studies as they pertain to the management of RCC patients

hubhopper

OBR Peer-Spectives

hubhopper